Also in this playlist...
This transcript is automatically generated
You are -- cancer research -- cancer treatment company you have a great new products so close to coming to market.
Can you tell us -- about it.
What we are developing is a system whereby you're immune system which is the strongest.
Agent for dealing with any disease and he's turned back on to go after the individual's cancer that's why it's called a cancer vaccines called you know there -- and what we do.
Is we either if tumor is operable we take the tumor out of the body instead of throwing -- out.
We send it to our facility in Memphis Tennessee where proprietary.
Process that we have.
We break out of that tumor all of the bio markers that the immune system has been turned off from going after.
And by doing that we -- do a blood draw.
And from the same patient and get their -- -- -- which are the masters of the immune system they direct.
Weapons within your immune system and in the laboratory.
We expose them and let those baby and yourself grow up in -- S adults.
They are then able to go back into the body just a shot like a flu shot like a flu shot eleven times over -- three year period.
And they go after nothing but the cancers so now what we have is -- it's nontoxic because it's not going after anything else meant hurting it.
Much more effective were eight years of survival and recurrence.
Compared to -- And that's an airlines talk about threat.
The average person with brain cancer -- survival time with typical treatment and radiation.
Is fourteen months correct.
That's and we've endured treatment with your immunization and it's three years that's correct.
Everything good as expected and you get the green light.
When when commercialization me.
Well when -- announced.
Phase three trial in both the United States which is trial right before you get to be commercialize its final trial.
Where the FDA says if we see good results it to 312.
Patient trial didn't 13 gets the a placebo and two -- get the vaccine in hand weren't fifty cents in the United States or bringing on.
Up to another thirty -- in Europe in the coming months and and we expect to be fully enroll.
With that 312 patient trial.
By the middle of next year and have final results -- we can go to begin.
Commercialization by the end -- -- -- My punishment and how much money are we talking this -- gonna have a huge went off.
Well I I don't think it's a windfall given that.
Cost 80000 dollars a year from chemotherapy right now.
And you aren't getting.
Something like two months of extra survival for 25% of the people who take it home and most of the people -- take -- are feeling the poisonous effects.
Whereas what will be charging is something in the range of 40000 dollars a year for about three years of treatment.
And the average is it is -- all -- -- -- -- -- through throughout of course we don't know in the phase three trial -- -- blind until we're done.
But the average for many patients who have taken in those early trials which is why we got to a phase two trial and he's he's three years of survival.
And two years to recurrence wouldn't when normally it's about seven months -- current.
And so it's much cheaper and it's lasted much longer and we have this is unheard of -- GBM we have several patients for -- regional problem started.
In the early two thousands that are out ten and eleven years.
And the normal would be two or 3%.
And and and where there's fully 13 of everybody into the vaccine is still alive after four years.
Are still alive after six years.
Those are very significant figures in.
We will be commercialized we will meet our endpoint in this phase three trial -- if we just show a six month extension.
Which is less than a third of what we saw in the phase one phase two trial.
The cost of cancer treatment.
It's growing by 20%.
And it -- noted that she said chemo treatments cost on average 80000 dollars a year something like that that's -- anger in which you hang -- -- -- streaming for three years for half of that.
Well it's 33 it's about 40000 dollars a year so grand total.
Over three years that's right -- in it it's something that range we haven't come up with -- -- outbreaks yet.
But we wanted to be available for as many people aware -- -- getting your funding from to do all the streets -- H basically all private funding.
Does Obama care and the new health care.
Changes affect champ.
It only affects us the extent that it raises V.
Being consciousness of the regulators and the public.
To the fact that medical costs are rising rapidly and what -- the fate provoked obamacare it is.
We have a more effective and lower cost approach to cancer treatment for all solid.
And operable -- inoperable tumors and it because of that.
We will lead the way hopefully -- in any more.
-- longer lasting and easier to administer.
And and cheaper approach with regards the health care is excellent because that's going -- So no matter what it was that obamacare we will be contributing to what everybody is after we lower cost is came -- typically covered under insurance.
Would you -- your solution -- in addition be covered under insurance let's put it this way.
I know that he's looking if -- if something is far more expensive and less effective gets covered.
When we are -- we would fully expect that we would be covered.
And that's the whole reason why whatever happens -- obamacare we will be in a position to help give more people longer lasting treatments.
And do it cheaper.
Thank you so much for coming on and sharing that with us less Goldman senior VP of business development at and it W bio we really do appreciate your time -- it was a real pleasure thing.
Filter by section